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Abstract
Introduction: Previous studies have shown insufficient diabetes control in patients with type 2 diabetes (T2DM). Diabetes Poland changed 
the target HbA1c and blood pressure (BP) values in diabetic patients in their practice guidelines in 2011, that were further sustained.
To assess the management and treatment choices in T2DM of more than ten years’ duration and the degree to which diabetic control 
criteria recommended by the Diabetes Poland clinical practice guidelines 2012 are being met.
Material and methods: ARETAEUS2-Grupa was a cross-sectional questionnaire-based study conducted in Poland in 2012 (April–June). 
It involved 1,740 patients of any age and both genders, with T2DM diagnosed more than ten years before the study, and recruited by 
randomly selected physicians.
Results: All patients received pharmacological treatment, most of them combination therapy or insulin in monotherapy. 40% of patients 
met the goal for HbA1c control (≤ 7%) and the median value of HbA1c was above the recommended threshold (7.2%). Only 8% of the 
total population met all three goals (HbA1c, BP and lipid levels), 26% — two goals, and 40% — only one goal. Over 25% of patients did 
not meet any of the treatment goals. 
Conclusions: We observed considerable deviations from treatment targets recommended by current clinical practice guidelines for 
patients with T2DM of more than ten years’ duration. The frequency of cardiovascular risk factors and late diabetes complications was 
high, while a relatively high percentage of patients was not examined for late diabetes complications. (Endokrynol Pol 2014; 65 (3): 158–168)
Key words: practice guideline; cross-sectional studies; diabetes mellitus type 2
Streszczenie
Wstęp: W poprzednich badaniach wykazano niewystarczającą kontrolę choroby u chorych na cukrzycę. Polskie Towarzystwo Diabe-
tologiczne zmieniło wartości docelowe HbA1c i ciśnienia tętniczego u chorych na cukrzycę w wytycznych z 2011 roku, które zostały 
utrzymane w kolejnych edycjach wytycznych. 
Badanie przeprowadzono w celu oceny leczenia cukrzycy i wyboru metod leczenia u chorych na cukrzycę typu 2 o czasie trwania > 10 lat oraz 
określenia stopnia spełniania kryteriów kontroli cukrzycy zalecanych w wytycznych Polskiego Towarzystwa Diabetologicznego z 2012 roku.
Materiał i metody: Badanie ARETAEUS2-Grupa było przekrojowym badaniem kwestionariuszowym przeprowadzonym w Polsce 
w 2012 roku (kwiecień–czerwiec). Badaniem objęto 1740 chorych na cukrzycę typu 2 w każdym wieku i obu płci rozpoznaną ponad 10 
lat przed rozpoczęciem badania, włączonych do badania przez losowo wybranych lekarzy.
Wyniki: Wszyscy chorzy otrzymywali leczenie farmakologiczne, większość — leczenie skojarzone lub insulinę w monoterapii. 40% chorych 
spełniło kryterium kontroli HbA1c (≤ 7%), a mediana odsetka HbA1c była powyżej zalecanej wartości (7,2%). W całej populacji jedynie 
8% chorych spełniło wszystkie kryteria kontroli choroby (HbA1c, ciśnienie tętnicze i profil lipidowy), 26% — dwa z tych kryteriów, 40% 
— jedno z tych kryteriów. Ponad 25% chorych nie spełniło żadnego z tych kryteriów. 
Wnioski: Zaobserwowano duże odstępstwa od celów leczenia zalecanych w aktualnych wytycznych postępowania u chorych na cukrzycę 
typu 2 o czasie trwania > 10 lat. Częstość występowania sercowo-naczyniowych czynników ryzyka i późnych powikłań cukrzycy była 
duża, a stosunkowo duży odsetek chorych nie był badany w kierunku późnych powikłań cukrzycy. (Endokrynol Pol 2014; 65 (3): 158–168)
Słowa kluczowe: wytyczne praktyki; badania przekrojowe; cukrzyca typu 2
This study was funded by an unrestricted educational grant from TEVA Pharmaceuticals Poland. The company had no role in the design of the 
questionnaire, or in the collection, analysis or interpretation of the data.
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Abbreviations
BMI — body mass index
BP — blood pressure 
CHD — coronary heart disease
T2DM — type 2 diabetes 
DP — Diabetes Poland
HbA1c — glycated haemoglobin 
HDL — high density lipoprotein
IQR — interquartile range 
LDL — low density lipoprotein 
SD — standard deviation 
Introduction
In Poland, 6.8% of the adult population has diabetes 
[1]. The ARETAEUS1 study, carried out in 2009, showed 
that a high proportion of patients with diabetes type 2 
(T2DM) of short duration had cardiovascular risk fac-
tors and late diabetes complications and over half of 
them did not meet any of the treatment goals outlined 
in the Diabetes Poland clinical practice guidelines [2, 
3]. The OPTIMO Study, which included patients with 
different diabetes durations, showed that the frequency 
of diabetes complications increased with diabetes 
duration and that glycaemic control worsened after 
several years of diabetes [4]. Diabetes Poland publishes 
practice guidelines for healthcare professionals annu-
ally, and changed its target HbA1c and blood pressure 
(BP) values in diabetic patients in 2011 [5–8]. Current 
practice guidelines recommend setting individualised 
treatment goals and treatment plans for patients with 
T2DM, which are based on age, life expectancy, comor-
bidities, risk of hypoglycaemia, patient education and 
patient preferences [7, 8]. Milder criteria (HbA1c ≤ 8%) 
are recommended for patients over 70 with long last-
ing T2DM, with a history of myocardial infarction or 
stroke [7, 8]. In the ARETAEUS2-Grupa study, we aimed 
to describe the characteristics of the T2DM population 
in Poland, including examining and diagnosing late 
diabetes complications, and examine diabetes control 
and treatment used both in patients with T2DM of 
short duration [9] and those with T2DM of more than 
ten years’ duration presented here.
Material and methods 
The aims of the study
ARETAEUS2-Grupa was a cross-sectional question-
naire-based study conducted in Poland (April–June 
2012). The study had two main aims: 1) to assess the 
methods of diabetes treatment used; and 2) to assess 
the degree to which the diabetic control criteria rec-
ommended by the Diabetes Poland clinical practice 
guidelines 2012 [7] are met. An additional aim included 
a description of the characteristics of the T2DM popu-
lation in Poland, including examining and diagnosing 
late diabetic complications. Diabetes was diagnosed 
using the widely accepted glycaemic criteria, which are 
consistent with the criteria of the American Diabetes 
Association [11], except HbA1c criteria for diagnosis of 
diabetes, which have not been accepted by Diabetes 
Poland yet [7]. 
The ARETAEUS2 Study had two arms: ARETAEUS2-
Grupa and ARETAEUS2-Market. Physicians and 
patients were recruited to those two arms separately. 
This paper on patients with T2DM lasting > 10 years 
concerns only patients participating in ARATAEUS2-
Grupa Study; the results for patients with T2DM of 
short duration have been reported elsewhere [9]. 
Patient inclusion criteria for the study 
ARETAEUS2-Grupa Study included two groups of 
patients of any age and both genders:
 — those diagnosed with type 2 diabetes within the pre-
vious two years (after 1 April, 2010) [9] who met the 
same inclusion criteria as in the ARETAEUS1 Study [2];
 — those diagnosed with type 2 diabetes more than ten 
years before the study commencement (before 2002), 
in order to obtain data on treatment and disease 
control in intermediate to long-lasting diabetes.
Recruitment of clinicians and their patients 
Two random samples of physicians were invited to 
participate in the study: non-diabetologists (mainly 
working in primary healthcare institutions) and dia-
betologists (specialists or physicians under training in 
diabetology, working in diabetes outpatient clinics). 
Random samples were drawn from a database 
containing about 85% of all physicians practicing in 
Poland. Physicians were asked to recruit at least five 
patients with type 2 diabetes diagnosed more than ten 
years before the study commencement (i.e. earlier than 
2002) during six weeks of the study duration. Patients 
were selected on a pseudorandom basis — the first 
two patients meeting the inclusion criteria from all the 
patients scheduled for a visit on that day. For a detailed 
description of recruitment procedures and sample size 
calculations, see our 2 years publication [9].
Questionnaire 
The questionnaire consisted of two parts and no 
question allowed the identification of personal data. 
A detailed description of the questionnaire was pub-
lished previously [9]. Briefly, the first part concerned 
the physician (specialisation, years since graduation, 
the mean number of patients with diabetes seen per 
week, availability of HbA1c test results on the day of 
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visit). The second part consisted of 24 patient-related 
questions including gender, age, duration of diabetes, 
medical history (cardiovascular events, hypertension, 
lipid disorders, history of cancer, diabetic complications) 
weight, height, test results (blood pressure, HbA1c, lipid 
levels), cigarette smoking status, fulfillment of treatment 
goals (BP, HbA1c, lipid levels), as well as details on dia-
betes, hypertension and hyperlipidaemia treatments 
used. Both parts of the questionnaire were completed 
by the physician. 
Statistical analysis
We compared the proportions of patients achieving 
treatment goals in the subgroups with chi2 test or 
Fischer exact test (when the expected values in any 
of the cells of a contingency table were below 5). For 
the comparison of the means, the t-test was used (for 
normal distribution), and the Mann-Whitney U test and 
Kruskal-Wallis test (for non-normal distribution of the 
variable). The distribution was estimated on the basis 
of skewness coefficient and graphical picture. The t-test 
for equal or nonequal variances was used depending 
on the result of the Levene’s test. All statistical analyses 
were conducted using SPSS v. 18.0.
Results
We received 1,740 valid questionnaires from 331 physi-
cians: 1,049 from 205 non-diabetologists and 691 from 
126 diabetologists (for details — see our 2 years paper 
[9]). Seventy percent of physicians participating in 
the study were specialists or undergoing training for 
a specialisation in internal medicine, 38% were diabe-
tologists in training or with completed training. Half of 
the participating physicians had graduated more than 
20 years before the study commencement, and half of 
them reported seeing 11–30 diabetic patients per week. 
Characteristics of patients 
Baseline characteristics and frequency of cardiovascular 
risk factors (Table I.) 
Glycaemic control
Eighty two percent of patients had HbA1c data avail-
able. Glycaemic control (HbA1c ≤ 7%) was achieved in 
40% of patients. This percentage did not change sub-
stantially after excluding patients with less restrictive 
glycaemic control according to the guidelines (Table 
II). For HbA1c distribution — see Appendix Fig. 1. Most 
patients had their HbA1c measured 1–12 months before 
the study (Appendix Table I).
Median HbA1c increased with the duration of dia-
betes, while the percentage of patients who met the 
glycaemic goal decreased slightly (Table III). 
Diabetes treatments used 
All patients received pharmacological treatment — most 
of them combination therapy or insulin in monotherapy 
(Table IV). More patients with HbA1c ≤ 7% received 
metformin with sulfonylurea therapy or sulfonylurea 
in monotherapy, while metformin with insulin or other 
drug and drug combinations were more commonly 
used in patients with HbA1c above 7% (Table IV). The 
use of the drugs differed in subgroups of patients de-
fined according to BMI (Table IV). The percentage of 
patients using metformin in combination with insulin 
increased with BMI, while the percentage of patients us-
ing sulfonylurea in monotherapy decreased with BMI. 
An analysis of the drug use according to the duration 
of the disease demonstrated that with the increasing 
duration of the disease, the proportions of patients 
receiving metformin in monotherapy or metformin 
with sulfonylurea decreased, while the proportion of 
patients receiving insulin in monotherapy increased 
significantly (Appendix Table II, III).
The number of diabetic drugs used by patients 
changed with the duration of diabetes (Appendix 
Fig. 2). 
Meeting treatment goals 
We analysed the number and type of treatment goals 
— BP < 140/90 mm Hg, LDL < 100 mg/dL or in case 
of CHD < 70 mg/dL, HbA1c ≤ 7.0% — met by patients 
in total and in subgroups (Table V, Appendix Table IV, 
V, Fig. 1). The data for all treatment goals was available 
for 1,190 patients. In the total population, only 8% of 
patients met all three goals, 26% met two goals and 
40% met one goal, while 25.6% did not meet any of the 
treatment goals (Fig. 1). In subgroups of patients (ana-
lysed by age, gender, BMI, duration of disease, types 
of diabetes treatment, etc. [Table V, Appendix Table IV, 
V]) the percentage of patients with all treatment goals 
met (HbA1c, LDL and BP levels goals) in different 
subgroups varied from 0 to 50% (in most cases it was 
less than 10%), while the percentage of patients with 
no treatment goals met was from 0 to 44.6% (in most 
cases between 15 and 30%). 
When we analysed how the treatment goals were 
met in different BMI subgroups, we noted significant 
differences between subgroups: more patients met all 
treatment goals in the low BMI subgroup, while more 
patients did not meet any treatment goals in the high-
est BMI subgroup.
Diabetic complications
Seventy six to 86% of patients were examined for dia-
betic complications and the most commonly reported 
complication was retinopathy. The frequency of diabe-
tes complications is shown in Figure 2. 
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Table I. Characteristics of the patient population with T2DM for more than ten years
Tabela I. Charakterystyka populacji chorych na cukrzycę typu 2 od ponad 10 lat
Total (n = 1,740)a
Gender (%) (n) (n = 1,682)
Female 53.9 (907)
Male 46.1 (775)
Age (n = 1,723), mean (SD) (years) 68 (9.8)
Time from diabetes diagnosis, median (IQR), months (n = 1,740) 156 (65)
Diabetes duration (%) (n)
 > 10–15 years 68.6 (1,193)
≥ 15–20 years 17.5 (305)
 > 20 years 13.9 (242)
BMI, mean (SD) [kg/m2] (n = 1,710) 30.4 (5.2)
HbA1c, median (IQR) (%) (n = 1431) 7.2 (1)
Total cholesterol, mean (SD) [mg/dL] (n = 1,668) 194 (45)
LDL cholesterol mean (SD) [mg/dL]
Patients with no CHD (n = 683) 111 (38)
Patients with CHD (n = 744) 110 (39)
HDL cholesterol, median (IQR) [mg/dL]
Female (n = 766) 50 (18)
Male (n = 668) 46 (15)b
Triglycerides, median (IQR) [mg/dL] (n = 1,629) 142 (74)
Lipid disordersc (%) (n) (n = 1,721) 83.1 (1,431)
Hypertensionc (%) (n) (n = 1,737) 91.7 (1,592)
BP systolic/diastolic, mean (SD) [mm Hg] (n = 1,723) 138 (15)/81 (10)
Current smokers (%) (n) 14.6 (244) 
History of ACSc (%) (n) (n = 1,702) 18.1 (308)
History of stable CHDc (%) (n) (n = 1,702) 48.5 (825)
History of strokec (%) (n) (n = 1,708) 8.9 (152)
History of TIAc (%) (n) (n = 1,707) 10.7 (183)
History of cancerc (%) (n) (n = 1,700) 6.5 (110)
Items in bold type were assessed as treatment goals. atotal number of valid responses; bsignificant difference between subgroups (p = 0.000);  
caccording to the physician report
ACS — acute coronary syndrome; BMI — body mass index; BP — blood pressure; CHD — coronary heart disease; HbA1c — glycated haemoglobin;  
HDL — high-density lipoprotein; IQR — interquartile range; LDL — low-density lipoprotein; SD — standard deviation; TIA — transient ischaemic attack
Table II. Glycaemic control in patients with T2DM for more than ten years
Table II. Kontrola glikemii u chorych na cukrzycę typu 2 od ponad 10 lat
Totala
 (n = 1,431)
After excluding patients 
with a history of cancer 
(n = 1,305)
After excluding 
patients with  
a history of cancer  
or over 80 years  
(n = 1,188)
Patients > 70 years 
old with ACS, stroke, 
TIA or with diabetes 
for > 20 years  
(n = 304)
After excluding patients 
> 70 years old with ACS, 
stroke, TIA or with diabetes 
for > 20 years  
(n = 534)
HbA1c ≤ 7% 39.8 (570) 40.0 (522) 39.2 (466) 39.5 (120) 37.3 (199)
HbA1c > 7% 60.2 (861) 60.0 (783) 60.8 (722) 60.5 (184) 62.7 (335)
HbA1c ≤ 8% – – – 77.3 (235) 72.7 (388)
HbA1c > 8% – – – 22.7 (69) 27.3 (146)
atotal number of valid responses
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Table III. Glycaemic control according to the duration of the disease in patients with T2DM for more than ten years
Tabela III. Kontrola glikemii w zależności od czasu trwania cukrzycy u chorych na cukrzycę typu 2 od ponad 10 lat
Total (n = 1,431)a Diabetes > 10–15 years Diabetes > 15–20 years Diabetes > 20 years
HbA1c, median (IQR) 7.2 (1) 7.3 (2) 7.38 (2)
HbA1c ≤ 7% 40.3 (386) 39.7 (104) 37.9 (80)
HbA1c > 7% 59.7 (572) 60.3 (158) 62.1 (131)
atotal number of valid responses
Discussion
The ARETAEUS2-Grupa Study provided information 
on risk factors, presence of diabetes complications and 
management of patients with T2DM of more than ten 
years’ duration. 
The current clinical practice guidelines [7, 8, 11, 12] 
recommend setting individualised treatment plans and 
treatment goals for patients with T2DM. We assessed 
the efficacy of diabetes treatment using the degree to 
which the criteria of diabetes control recommended by 
the Diabetes Poland clinical practice guidelines are met 
[7] in a population of patients with T2DM lasting for 
more than ten years, and we observed changes in the 
pattern of drugs used. 
Median HbA1c increased with the duration of the 
disease and the percentage of patients meeting this goal 
slightly decreased with longer duration of the disease 
and compared to T2DM of short duration (40% vs. 62%) 
[9]. Also, the percentage of patients meeting all treat-
ment goals was slightly lower in this study compared 
to T2DM of short duration (8% vs. 11%) [9]. The results 
remain valid as the current 2013 recommendations are 
consistent with those published in 2012 in terms of 
treatment goals criteria [8]. On the other hand, current 
practice guidelines recommend milder criteria (HbA1c 
Table IV. Current diabetes treatment according to HbA1c levels and BMI in patients with T2DM for more than ten years
Tabela IV. Obecne leczenie cukrzycy w zależności od wartości HbA1c i BMI u chorych na cukrzycę typu 2 od ponad 10 lat
Overall  
(n = 1,620)a
HbA1c (n = 1,331) BMI (n = 1,593)
Exclusive drug categories n (%) ≤ 7.0%  > 7.0% < 25 (n = 193) 25–30 (n = 639) > 30 (n = 761)
No antidiabetic drugs 0 0 0 0 0 0
Metformin in monotherapy 6.6 (107) 9.7 (51)  3.0 (24)b 8.3 (16) 6.4 (41) 6.2 (47)
Metformin and SU 22.9 (371)  28.2 (148)  15.5 (125)b 22.8 (44) 26.8 (171) 20.0 (152)c 
Metformin and insulin 29.1 (472)  25.6 (134)  35.9 (290)b 19.7 (38) 23.5 (150) 36.5 (278)b
Metformin and other drug  
(not SU or insulin)
1.0 (16)  1.0 (5)  0.7 (6) 0 0.8 (5) 1.3 (10)
SU in monotherapy 4.1 (66)  6.1 (32)  1.1 (9)b 9.3 (18) 4.2 (27) 2.6 (20)b 
SU and insulin 1.9 (31)  1.9 (10)  2.0 (16) 1.0 (2) 1.6 (10) 2.1 (16)
SU and other drug  
(not metformin or insulin)
1.0 (17)  1.1 (6)  0.9 (7) 3.1 (6) 1.1 (7) 0.4 (3)d 
Insulin in monotherapy 17.5 (283)  16.4 (86) 20.4 (165) 25.9 (50) 18.8 (120) 14.5 (110)e 
Other drug or drug combinationsg 15.9 (257) 9.9 (52) 20.4 (165)b 9.8 (19) 16.9 (108) 16.4 (125)
Overall  
(n = 1,705)
HbA1c (n = 1,405) BMI (n = 1,676)
Drugs in monotherapy or combined (%) (n) ≤ 7.0% > 7.0% < 25 (n = 206) 25–30 (n = 672) > 30 (n = 798)
Metformin 74.2 (1,265)  81.6 (525)  83.3 (334) 59.2 (122) 73.8 (496) 78.6 (627)b 
SU 42.8 (726) 36.1 (231)  46.6 (183)b 44.4 (92) 47.7 (319) 38.1 (302)e
Acarbose 11.0 (184)  5.5 (35)  7.0 (27)f 10.3 (21) 11.5 (75) 10.5 (82)
Insulin 61.4 (1,046)  11.2 (71)  30.1 (118)b 53.4 (110) 57.2 (383) 67.0 (535)b
GLP-1 agonist 0.4 (7)  0.2 (1)  0.6 (5) 0 0.3 (2) 0.6 (5)
DPP-4 inhibitor 0.7 (12)  1.9 (12) 2.4 (9) 0.5 (1) 0.9 (6) 0.6 (5)
atotal number of valid responses; bstatistically significant differences between the subgroups, chi2, p = 0.000; cp = 0.11;dp = 0.003; ep = 0.001; fp = 0.027;  
galso included three or more drug combinations including metformin; GLP-1 — glucagon-like peptide-1; DPP-4 — dipeptidyl peptidase-4; SU — sulfonylurea
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≤ 8%) for patients over 70 with long lasting T2DM, 
with a history of myocardial infarction or stroke [7,8]. 
In such patients included in our study, the percentage 
of those meeting the general goal ≤ 7% was similar to 
the total population; excluding such patients also did 
not change the results. 
Compared to patients with T2DM of short dura-
tion [9], those with longer lasting and more advanced 
disease received oral drugs in monotherapy less 
frequently (metformin 6.6% vs. 42.3%, sulfonylurea 
4.1% vs. 9.4%) and more frequently were treated with 
insulin in monotherapy (17.5% vs. 5.8%) or both with 
metformin and insulin (29.1% vs. 5.7%), and the lat-
ter scheme was the most common drug combination 
used in those patients, particularly in a subgroup 
with BMI > 30 kg/m2 (36.5% vs. 6.3% in patients with 
T2DM of short duration). 
It is interesting to note that after ten years of dia-
betes duration,13% of patients were still treated with 
only one oral antidiabetic drug. This finding is similar 
to the one in The Polish Diabetes Registry for Adults 
project [13], where 17.6% of patients were treated with 
Table V. Meeting treatment goals in patients with T2DM for more than ten years: subgroup analysis by treatment type, %(n); 
treatment goals: B < 140/90 mm Hg, C < 100 mg/dL or if CHD < 70 mg/dL, A ≤ 7.0%
Tabela V. Spełnianie celów leczenia u chorych na cukrzycę typu 2 od ponad 10 lat: analiza w podgrupach w zależności od 
rodzaju leczenia, % (n); cele leczenia: B < 140/90 mm Hg; C < 100 mg/dl lub jeśli choroba wieńcowa < 70 mg/dl, A ≤ 7%
Subgroup Number of patients in 
subgroupa
Percentage of patients with goals met (A, B, C)
3 goals met Only 2 goals metb Only 1 goal metc 0 goals met (all not met)
No antidiabetic drugs Yes (n = 0) 0 0 0 0
No (n = 1,101) 8.4 (93) 26.2 (288) 40.0 (440) 25.4 (280)
Metformin in monotherapyd Yes (n = 67) 19.4 (13) 35.8 (24) 34.3 (23) 10.4 (7)
No (n = 1,034) 7.7 (80) 25.5 (264) 40.3 (417) 26.4 (273)
Metformin and SUd Yes (n = 233) 10.7 (25) 36.1 (84) 34.3 (80) 18.9 (44)
No (n = 868) 7.8 (68) 23.5 (204) 41.5 (360) 27.2 (236)
Metformin and insuline Yes (n = 345) 7.2 (25) 20.6 (71) 41.7 (144) 30.4 (105)
No (n = 756) 9.0 (68) 28.7 (217) 39.2 (296) 23.1 (175)
Metformin and a drug other 
than SU and insulin
Yes (n = 9) 11.1 (1) 11.1 (1) 33.3 (3) 44.4 (4)
No (n = 1,092) 8.4 (92) 26.3 (287) 40.0 (437) 25.3 (276)
Insulin in monotherapy Yes (n = 203) 5.9 (12) 26.1 (53) 44.8 (91) 23.2 (47)
No (n = 898) 9.0 (81) 26.2 (235) 38.9 (349) 25.9 (233)
Insulin and other drugd Yes (n = 500) 6.4 (32) 18.8 (94) 43.0 (215) 31.8 (159)
No (n = 601) 10.1 (61) 32.3 (194) 37.4 (225) 20.1 (121)
aonly the patients for whom data on all treatment goals was available; bexcludes patients from the previous column who met all three goals; cexcludes patients from  
the previous columns who met more than one goal; dsignificant difference between the groups, p = 0.000; ep = 0.007. A — HbA1c; B — blood pressure;  
C — LDL-cholesterol; CHD — coronary heart disease; other — see Table I
Figure 1. Proportions of patients (total population) with T2DM for more than ten years meeting treatment goals according to the 
Diabetes Poland 2012 guidelines
Rycina 1. Odsetek chorych na cukrzycę typu 2 od ponad 10 lat (cała populacja) spełniających cele leczenia zgodnie z wytycznymi 
Polskiego Towarzystwa Diabetologicznego z 2012 roku
164
PR
A
C
E 
O
RY
G
IN
A
LN
E
Management and treatment goals in Polish patients with type 2 diabetes   Małgorzata M. Bała et al.
Figure 2. Proportion of patients examined for and diagnosed with 
diabetic complications
Rycina 2. Odsetek chorych badanych w kierunku powikłań 
cukrzycy i z rozpoznanymi powikłaniami cukrzycy
a single oral drug (metformin or sulfonyurea), however 
their diabetes duration was shorter (mean 9.7 years). 
This single drug treatment despite ten years of 
diabetes duration may be explained by meeting the 
goal because of natural history of the disease, proper 
dosing of an oral drug or good patient adherence to 
physician recommendations and not meeting the goal 
and clinical inertia — failure of healthcare provider to 
intensify treatment when indicated [14].
In our study, the possible explanation may be meet-
ing the goal with a single oral drug — when each of the 
diabetes duration categories and drug treatments were 
split by HbA1c value, it was noted that many patients 
with a single oral drug had HbA1c ≤ 7%. However, the 
cross sectional nature of the study calls for cautious 
interpretation of the results. 
When analysing meeting treatment goals in sub-
groups divided by treatment type, we noted significant 
differences between them. In subgroup of metformin 
in monotherapy vs. other treatments and combina-
tions (also including metformin combined with other 
drugs) and metformin combined with sulfonylurea vs. 
other treatments or combinations, more patients had 
three or two treatment goals met and fewer patients 
did not meet any of the goals. On the other hand, in 
a subgroup of metformin with insulin vs. other treat-
ments and combinations and insulin with other drugs 
vs. other treatments or combinations, more patients had 
one or none of the goals met and fewer patients had 
three or two goals met. However this data should be 
interpreted cautiously due to the cross-sectional nature 
of the study — these patients may have begun insulin 
treatment due to not meeting HbA1c goal.
In our patient population, only mean BP values 
were below the threshold recommended in the Diabetes 
Poland guidelines (< 140/90 mm Hg), while median 
HbA1c value and mean values of total cholesterol and 
LDL-cholesterol were above recommended thresholds 
(HbA1c ≤ 7%, and for total cholesterol < 175 mg/dL for 
LDL cholesterol < 100 mg/dL or < 70 mg/dL in patients 
with CHD). In patients with T2DM of short duration, 
not only mean BP but also the median values of HbA1c 
were below the general thresholds recommended in 
the guidelines [9].
Several epidemiological studies have documented 
the treatment and control of type 2 diabetes in Poland 
[2–4, 13, 15–19], but none of them has specifically ad-
dressed patients with T2DM of more than ten years’ 
duration. Only two of those previous studies provided 
some data on diabetes control by the duration of the 
disease which enables comparisons with the current 
study. The OPTIMO study showed that 37% of patients 
with diabetes lasting for more than ten years had HbA1c 
≤ 7%, which is similar to the percentage reported in the 
current study (40%) [4] and the DINAMIC study [17, 18]. 
Studies conducted in other countries also showed 
that most diabetic patients do not meet their HbA1c, 
BP and lipid treatment goals [20–26]. The most recent 
survey in U.S. patients [26] showed improvements in 
diabetes control over 12 years, but only 14% of patients 
met all their treatment goals (HbA1c ≤ 7% and individu-
alised goals, BP < 130/80 mm Hg and LDL-cholesterol 
< 100 mg/dL and < 70 mg/dL in those with CHD) and 
achieved non-smoking status, which is slightly better 
than in our study (8%). Over 70% of U.S. patients had 
annual eye and foot examinations, while in our study 
the percentages were higher. However the U.S. survey’s 
population included all diabetics independent of dis-
ease duration, with only 34% of patients with T2DM 
lasting for five to 15 years. 
Diabetes Poland guidelines recommend regularly 
examining patients with T2DM for late diabetes com-
plications since diagnosis (every year for nephropathy 
and retinopathy). However, as we observed in our study 
— during ten or more years since T2DM diagnosis, 
17% of patients were not examined for nephropathy, 
14% were not examined for retinopathy and 24% 
were not examined for diabetic foot, which must be 
worrying. One possible explanation for this situation 
could be restricted access to recommended examina-
tions — a recent study has shown that specialised 
care provided by diabetes outpatient clinics in Poland is 
not used by more than half of the people suffering from 
diabetes (60.3%), which may be caused by limited access 
to those services [27]. Another explanation could be poor 
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communication between different diabetes healthcare 
providers, mainly primary care and diabetes specialists, 
or not adhering to the practice guidelines. This can also 
be attributed to clinical inertia, the previously explained 
failure of the healthcare provider to intensify treatment 
when indicated. Clinical inertia is ascribed mainly to three 
factors: overestimation of care provided (i.e. physicans 
tend to overestimate the frequency of practices such as 
foot examinations, dilated-eye examinations, haemoglobin 
A1c measurement, and urine protein screening compared 
to analyses of large claims databases [14, 28]); the use of 
‘soft’ reasons to avoid intensification of therapy (i.e. lack 
of time at office visits, previous patient nonadherence [14, 
29]); and lack of education, tools, training to support active 
care for people with chronic diseases [14, 29]. 
However, due to the cross-sectional nature of our 
study, we are unable to recognise the reason for this 
situation. 
There are some limitations of our study. First is 
the cross-sectional design of the study, which does 
not provide us with long-term data. Since the study 
included patients with different diabetes durations, 
the median or mean values of the parameters may not 
be informative due to recommended individualisa-
tion of the therapy. To provide more information, we 
also analysed treatment goals by T2DM duration. In 
addition, to ensure the representative nature of our 
study population and to adequately reflect an aver-
age T2DM patient, we randomly selected physicians 
participating in our study separately for diabetologists 
and non-diabetologists (stratified by size of the place 
of residence) and we introduced patient selection on 
a pseudo-random basis. 
The study lacked the verification of data collected 
from the physicians, which is also a limitation. Since 
the reliability of the data was dependent on the physi-
cians, this may be associated with bias toward better 
results, although in fact the degree of diabetes control 
might even be less satisfactory than shown in the cur-
rent study. 
The number of patients for whom HbA1c values 
were available, although higher than in patients with 
T2DM of short duration [9], is also a limitation of our 
study. Eighty two percent of patients had HbA1c values 
recorded, with only 44% having HbA1c measured one 
to six months before the study. Many physicians do not 
follow recommended HbA1c measurement frequency 
and many patients do not know how important this 
marker of diabetes control is [13]. These facts may af-
fect the reliability of the assessment of diabetes care 
quality in Poland.
We can only speculate why the control of diabetes is 
so suboptimal. It could be explained by poor access to 
education, low number of nurses or diabetes educators, 
restricted access to recommended examinations, diabe-
tes specialists or drugs (due to lack of reimbursement 
of new drugs, such as incretins), poor communication 
between different diabetes healthcare providers, and/or 
lack of understanding of the nature of disease by both 
physicians and patients. Moreover, suboptimal coopera-
tion of specialists from many fields of medicine in the 
management of this complex disease makes treating it 
very demanding. 
Conclusions
We have observed considerable deviations from treat-
ment targets recommended by current clinical practice 
guidelines and poorer disease control in patients with 
T2DM of more than ten years’ duration compared to 
those with T2DM of short duration. The frequency of 
cardiovascular risk factors and late diabetes complica-
tions was high, while there was a relatively high per-
centage of patients who were never examined for late 
diabetes complications. A large body of evidence exists 
that supports a variety of interventions to improve dia-
betes outcomes, and patients may need to have better 
access to care where many issues, beyond glycaemic 
control, could be addressed. 
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Appendix Table I. Time of last HbA1c measurement and diabetes duration (n = 1,528)
Dodatek. Tabela I. Ostatni wynik HbA1c a czas trwania cukrzycy (n = 1528)
Last HbA1c measurement before the study % (n) Median diabetes duration, months (IQR)
 < week 9.0 (137) 171 (77)
 < 1 month 8.8 (135) 148 (74)
1–3 months 23.0 (352) 156 (65)
4–6 months 20.7 (317) 157 (67)
7–12 months 18.8 (287) 157 (63)
 > 12 months 11.1 (169) 160 (64)
Not known 8.6 (131) 156 (55)
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Appendix Table II. Current diabetes treatment according to diabetes duration in patients with T2DM for more than ten years
Dodatek. Tabela II. Obecne leczenie cukrzycy w zależności od czasu trwania choroby u chorych na cukrzycę typu 2 od ponad 10 lat
Exclusive drug categories (%) (n); n = 1,620a
10–15 years (n = 1,108)  > 15–20 years (n = 287)  > 20 years (n = 225)
No antidiabetic drugs 0 0 0
Metformin in monotherapyb 8.3 (92) 3.8 (11) 1.8 (4)
Metformin and SUb 26.1 (289) 22.6 (65) 7.6 (17)
Metformin and insulin 27.9 (309) 32.4 (93) 31.3 (70)
Metformin and other drug (not SU or insulin) 1.3 (14) 0.3 (1) 0.4 (1)
SU in monotherapy 4.7 (52) 2.4 (7) 3.1 (7)
SU and insulin 1.4 (16) 3.1 (9) 2.7 (6)
SU and other drug (not metformin or insulin) 0.9 (10) 1.4 (4) 1.3 (3)
Insulin in monotherapyb 13.3 (147) 19.2 (55) 36.0 (81)
Other drug or drug combinations 16.2 (179) 14.6 (42) 16.0 (36)
Drugs in monotherapy or combined (%) (n)
10–15 years (n = 1,166)  > 15–20 years (n = 302)  > 20 years (n = 237)
Metforminb 78.8 (919) 72.2 (218) 54.0 (128)
SUb 47.3 (549) 40.7 (122) 23.4 (55)
Acarbose 10.5 (120) 11.1 (33) 13.3 (31)
Insulinb 55.9 (651) 65.1 (196) 83.6 (199)
GLP-1 agonist 0.6 (7) 0 0
DPP-4 inhibitor 0.7 (8) 0.7 (2) 0.9 (2)
atotal number of valid questionnaires; bstatistically significant differences between the subgroups, p = 0.000
Appendix Table III. Current diabetes treatment according to diabetes duration and HbA1c in patients with T2DM for more 
than ten years (n = 1,331)
Dodatek. Tabela III. Obecne leczenie cukrzycy w zależności od czasu trwania choroby i wartości HbA1c u chorych na cukrzycę 
typu 2 od ponad 10 lat
Exclusive drug categories (%) (n)
10–15 years (n = 890)  > 15–20 years (n = 245)  > 20 years (n = 196)
HbA1c ≤  
7.0%  
(n = 356)
HbA1c >  
7.0%  
(n = 534)
HbA1c ≤  
7.0%  
(n = 97)
HbA1c >  
7.0%  
(n = 148)
HbA1c ≤  
7.0%  
(n = 71)
HbA1c >  
7.0%  
(n = 125)
No antidiabetic drugs 0 0 0 0 0 0
Metformin in monotherapy 11.5 (41) 4.3 (23)a 7.2 (7) 0a 4.2 (3) 0.8 (1)a
Metformin and SU 31.5 (112)b 17.2 (92)c 27.8 (27)b 19.6 (29)c 12.7 (9)b 3.2 (4)c
Metformin and insulin 21.9 (78)d 37.3 (199) 32.0 (31) 35.1 (52) 35.2 (25) 31.2 (39)
Metformin and other drug  
(not SU or insulin)
1.1 (4) 1.1 (6) 1.0 (1) 0 0 0
SU in monotherapy 7.9 (28)e 0.9 (5) 2.1 (2) 1.4 (2) 2.8 (2) 1.6 (2)
SU and insulin 1.7 (6) 1.3 (7) 3.1 (3) 3.4 (5) 1.4 (1) 3.2 (4)
SU and other drug  
(not metformin or insulin)
0.8 (3)f 0.9 (5) 0f 1.4 (2) 4.2 (3)f 0
Insulin in monotherapyb 13.8 (49)g 14.6 (78)c 16.5 (16)g 23.0 (34)c 29.6 (21)g 42.4 (53)c
Other drug or drug combinations 9.8 (35) 22.3 (119) 10.3 (10) 16.2 (24) 9.9 (7) 17.6 (22)
Drugs in monotherapy or combined (%) (n); n = 1405
10–15 years (n = 939)  > 15–20 years (n = 259) > 20 years (n = 207)
HbA1c ≤  
7.0%  
(n = 379)
HbA1c >  
7.0%  
(n = 560)
HbA1c ≤  
7.0%  
(n = 103)
HbA1c >  
7.0%  
(n = 156)
HbA1c ≤  
7.0%  
(n = 78)
HbA1c >  
7.0%  
(n = 129)
Metformin 76.0 (288)e 81.1 (454)c 75.7 (78)e 69.9 (109)c 62.8 (49)e 50.4 (65)c
SU 50.9 (191)h 39.4 (218)c 41.2 (42)h 36.8 (57)c 28.2 (22)h 16.5 (21)c
Acarbose 8.2 (30) 12.4 (68) 8.0 (8) 11.8 (18) 11.7 (9) 14.3 (18)
Insulin 45.2 (168)c 71.8 (405)c 58.8 (60)c 73.7 (115)c 75.3 (58) 91.6 (120)c
GLP-1 agonist 0.3 (1) 0.9 (5) 0 0 0 0
DPP-4 inhibitor 0.3 (1) 1.3 (7) 0 1.3 (2) 0 0.8 (1)
astatistically significant differences between the age subgroups within HbA1c category, p = 0.007; bp = 0.006; cp = 0.000; dp = 0.018; ep = 0.049; fp = 0.025;  
gp = 0.005; hp = 0.001
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Appendix Table IV. Meeting treatment goals in patients with T2DM for more than ten years: subgroup analysis by patient 
characteristics, %(n); treatment goals: B < 140/90 mm Hg, C < 100 mg/dL or if CHD < 70 mg/dL, A ≤ 7.0% (total = 1,190)a
Dodatek. Tabela IV. Spełnianie celów leczenia u chorych na cukrzycę typu 2 od ponad 10 lat: analiza w podgrupach 
w zależności od charakterystyki chorych, % (n); cele leczenia: B < 140/90 mm Hg; C < 100 mg/dl lub jeśli choroba wieńcowa 
< 70 mg/dl, A ≤ 7% (łącznie = 1190) 
Subgroup Number of patients in 
the group A
Percentage of patients with goals met
3 goals 
met
Only 2 goals met (excludes patients from 
the previous column who met all 3 goals)
Only 1 goal met (excludes patients from the 
previous columns who met more than 1 goal)
0 goals met
A, B, C any two B and C A and C A and B anyone B C A A, B, C, 
all not met
Male
Age  < 40 yrs (n = 2) 50.0 (1) 50.0 (1) 50.0 (1) 0 0 0 0 0 0 0
≥ 40 yrs (n = 538) 7.8 (42) 26.2 (141) 6.7 (36) 4.5 (24) 15.1 (81) 40.3 (217) 17.8 (96) 7.6 (41) 14.9 (80) 25.7 (138)
BMIb < 25 (n = 65) 13.8 (9) 32.3 (21) 9.2 (6) 1.5 (1) 21.5 (14) 38.5 (25) 23.1 (15) 4.6 (3) 10.8 (7) 15.4 (10)
25–30 (n = 237) 8.9 (21) 28.7 (68) 6.3 (15) 5.9 (14) 16.5 (39) 40.1(95) 21.1 (50) 5.5 (13) 13.5 (32) 22.4 (53)
> 30 (n = 242) 5.4 (13) 20.7 (50) 5.8 (14) 3.7 (9) 11.2 (27) 41.3 (100) 13.6 (33) 10.3 (25) 17.4 (42) 32.6 (79)
Female
Age < 40 yrs (n = 7) 28.6 (2) 0 0 0 0 71.4 (5) 28.6 (2) 14.3 (1) 28.6 (2) 0
> 40 yrs (n = 589) 8.8 (52) 27.0 (159) 4.6 (27) 6.8 (40) 15.6 (92) 38.7 (228) 18.7 (110) 7.6 (45) 12.4 (73) 25.5 (150)
BMIc < 25 (n = 77) 16.9 (13) 40.0 (30) 7.8 (6) 3.9 (3) 27.3 (21) 31.2 (24) 19.5 (15) 3.9 (3) 7.8 (6) 13.0 (10)
25–30 (n = 206) 8.7 (18) 24.8 (51) 2.9 (6) 6.8 (14) 15.0 (31) 44.2 (91) 19.4 (40) 9.2 (19) 15.5 (32) 22.3 (46)
> 30 (n = 307) 7.5 (23) 24.8 (76) 4.9 (15) 6.8 (21) 13.0 (40) 37.8 (116) 18.2 (56) 7.8 (24) 11.7 (36) 30.0 (92)
aonly the patients for whom data on all treatment goals was available; bsignificant difference between the groups, p = 0.003; cp = 0.005; differences in any and 
specific percentages are the result of rounding up. A — HbA1c; B — blood pressure; C — LDL-cholesterol; CHD — coronary heart disease; other — see Table I
Appendix Table V. Meeting treatment goals in patients with T2DM for more than ten years: subgroup analysis by HbA1c 
goal and diabetes duration, %(n); treatment goals: B < 140/90 mm Hg, C < 100 mg/dL or if CHD < 70 mg/dL, A ≤ 7.0%
Dodatek. Tabela V. Spełnianie celów leczenia u chorych na cukrzycę typu 2 od ponad 10 lat: analiza w podgrupach w zależności od celu 
HbA1c i czasu trwania cukrzycy, % (n); cele leczenia: B < 140/90 mm Hg; C < 100 mg/dl lub jeśli choroba wieńcowa < 70 mg/dl, A ≤ 7%
Subgroup Number of patientsa 3 goals met Only 2 goals metb Only 1 goal metc 0 goals met
A ≤ 7% 506 19.4 (98) 48.6 (246) 32.0 (162) 0
A > 7% 684 0 9.8 (67) 45.6 (312) 44.6 (305)
Diabetes 10–15 years 804 7.8 (63) 26.5 (213) 38.8 (312) 26.9 (216)
Diabetes 16–20 years 210 9.5 (20) 24.8 (52) 41.4 (87) 24.3 (51)
Diabetes > 20 years 176 8.5 (15) 27.3 (48) 42.6 (75) 21.6 (38)
aonly the patients for whom data on all treatment goals was available; bexcludes patients from the previous column who met all three goals; cexcludes patients from the 
previous columns who met more than one goal. A — HbA1c; B — blood pressure; C — LDL-cholesterol; CHD — coronary heart disease; other — see Table I
Appendix Figure 2. Number of antidiabetic drugs used by patients with 
T2DM for more than ten years by the duration of the disease
Dodatek do ryciny 2. Liczba leków przeciwcukrzycowych stosowanych 
przez chorych na cukrzycę typu 2 od ponad 10 lat w zależności od czasu 
trwania choroby
Appendix Figure 1. Distribution of HbA1c 
values in patients with T2DM for more than 
ten years
Dodatek. Rycina 1. Rozkład wartości HbA1c 
u chorych na cukrzycę typu 2 od ponad 10 lat
